…
Elixinol Wellness Limited, a holding company, produces and sells human nutrition, human wellness, pet wellness, and superfood ingredients in Australia, the Americas, and internationally. The company offers its products under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands. It distributes its products through grocery, wholesale, and e-commerce channels for white label customers, as well as food, beverage, and beauty manufacturers. In addition, the company engages in the manufacture and distribution of hemp-derived cannabidiol (CBD) products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is based in Newtown, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Elixinol Wellness Ltd manufactures and sells hemp-derived CBD and plant-based wellness products to consumer health markets in Australia and selected international channels. Long-term growth may be supported by rising consumer acceptance of CBD, expansion of e-commerce and retail distribution, and ongoing product development, which may make the company attractive to investors seeking exposure to the consumer wellness segment.
Principal risks are regulatory uncertainty for CBD products, strong competition in the nutraceuticals market, and execution or supply-chain challenges that could impair revenue and margins.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -6.04M | -5.31M | -7.50M | -10.57M | -17.09M |
| Net income | -5.50M | -1.72M | -7.51M | -10.57M | -17.02M |
| Selling general administrative | - | 5.48M | 6.17M | 8.08M | 12.95M |
| Selling and marketing expenses | - | 2.39M | 1.82M | 2.29M | 3.68M |
| Gross profit | 0.75M | 5.36M | -1.80M | 3.24M | 4.90M |
| Reconciled depreciation | - | 1.04M | 0.60M | 0.72M | 2.30M |
| Ebit | -4.98M | -5.05M | -7.40M | -9.01M | -11.67M |
| Ebitda | -4.11M | -4.01M | -6.81M | -8.29M | -10.18M |
| Depreciation and amortization | 0.87M | 1.04M | 0.60M | 0.72M | 1.49M |
| Operating income | -4.98M | -3.47M | -6.43M | -9.01M | -11.67M |
| Other operating expenses | 20.48M | 18.42M | 14.73M | 17.06M | 24.95M |
| Interest expense | 0.49M | 0.21M | 0.10M | -0.05M | 5.42M |
| Tax provision | - | -3.59M | 0.00M | 0.00M | -0.07M |
| Interest income | - | 0.03M | 0.21M | 0.02M | 0.01M |
| Net interest income | - | -0.18M | 0.11M | -0.05M | -0.06M |
| Income tax expense | -0.54M | -3.59M | 0.00M | 0.00M | -0.07M |
| Total revenue | 15.50M | 14.96M | 8.27M | 7.05M | 9.34M |
| Total operating expenses | 5.73M | 8.82M | 9.88M | 13.24M | 20.50M |
| Cost of revenue | 14.75M | 9.60M | 10.07M | 3.82M | 4.44M |
| Total other income expense net | -1.06M | -1.84M | -1.04M | -1.56M | -5.42M |
| Net income from continuing ops | - | -1.72M | -7.51M | -10.57M | -27.85M |
| Net income applicable to common shares | - | -1.72M | -7.51M | -10.57M | -17.02M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 15.96M | 18.45M | 11.71M | 13.48M | 25.33M |
| Intangible assets | 2.02M | 4.81M | - | 0.15M | 0.46M |
| Other current assets | 0.45M | 0.91M | 2.08M | 0.17M | 0.17M |
| Total liab | 8.51M | 8.42M | 5.25M | 4.33M | 6.25M |
| Total stockholder equity | 7.45M | 10.03M | 6.46M | 9.16M | 19.08M |
| Other current liab | 1.67M | 1.87M | 1.64M | 1.35M | 1.10M |
| Common stock | 229.88M | 228.29M | 222.57M | 218.12M | 218.06M |
| Capital stock | - | - | - | 218.12M | 218.06M |
| Retained earnings | -233.29M | -227.88M | -226.15M | -218.65M | -208.07M |
| Good will | 3.13M | 1.37M | - | - | 0.00M |
| Other assets | - | - | 0.00M | 0.08M | 0.18M |
| Cash | 1.41M | 1.08M | 0.71M | 2.86M | 12.65M |
| Total current liabilities | 6.64M | 4.99M | 4.99M | 3.44M | 4.71M |
| Current deferred revenue | 0.05M | - | 0.52M | - | 1.07M |
| Net debt | 2.54M | 0.86M | 0.55M | -0.96M | -9.93M |
| Short term debt | 3.40M | 1.30M | 1.07M | 1.02M | 1.18M |
| Short long term debt | - | - | - | 0.32M | 0.43M |
| Short long term debt total | 3.95M | 1.94M | 1.26M | 1.90M | 2.71M |
| Other stockholder equity | - | - | - | 9.09M | 9.09M |
| Property plant equipment | - | - | - | 1.11M | 2.48M |
| Total current assets | 5.70M | 7.18M | 8.18M | 9.31M | 19.59M |
| Long term investments | - | - | - | 2.83M | 2.62M |
| Net tangible assets | - | - | - | 9.01M | 18.61M |
| Short term investments | - | - | - | 0.17M | 0.17M |
| Net receivables | 1.19M | 1.30M | 1.72M | 3.97M | 2.97M |
| Long term debt | - | - | - | 0.25M | 0.25M |
| Inventory | 2.66M | 3.89M | 3.66M | 1.74M | 2.20M |
| Accounts payable | 1.52M | 1.82M | 1.76M | 1.08M | 1.36M |
| Accumulated other comprehensive income | 10.87M | 9.61M | 10.04M | 9.68M | 9.09M |
| Non currrent assets other | 0.08M | 3.67M | 2.35M | 0.08M | 0.18M |
| Non current assets total | 10.26M | 11.27M | 3.54M | 4.17M | 5.74M |
| Capital lease obligations | - | - | - | 1.33M | 2.04M |
| Long term debt total | - | - | - | 0.82M | 1.47M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.07M | -1.04M | -0.87M | -0.01M |
| Change to liabilities | - | - | - | -0.90M | -0.61M |
| Total cashflows from investing activities | -0.22M | -0.07M | -1.04M | -0.87M | 0.17M |
| Net borrowings | - | 0.86M | 0.30M | -0.76M | -1.05M |
| Total cash from financing activities | 3.65M | 3.92M | 1.61M | -0.76M | -1.16M |
| Change to operating activities | - | - | - | 0.23M | 0.35M |
| Net income | -5.50M | -1.72M | -7.51M | -10.57M | -27.85M |
| Change in cash | 0.33M | 0.37M | -2.16M | -9.79M | -15.09M |
| Begin period cash flow | 1.08M | 0.71M | 2.86M | 12.65M | 27.74M |
| End period cash flow | 1.41M | 1.08M | 0.71M | 2.86M | 12.65M |
| Total cash from operating activities | -3.21M | -3.47M | -2.76M | -9.85M | -14.07M |
| Issuance of capital stock | - | 4.66M | 2.25M | - | - |
| Depreciation | 0.87M | 1.04M | 0.60M | 0.72M | 1.49M |
| Other cashflows from investing activities | 0.00M | 2.27M | -1.22M | -0.86M | 0.46M |
| Change to inventory | 1.23M | 1.73M | 0.47M | 0.23M | -0.24M |
| Change to account receivables | 0.42M | 0.54M | 1.37M | 0.14M | -2.01M |
| Sale purchase of stock | - | -0.56M | -0.20M | - | -0.11M |
| Other cashflows from financing activities | -0.30M | -1.04M | -0.74M | -0.76M | -1.05M |
| Change to netincome | - | - | - | 1.52M | 4.02M |
| Capital expenditures | 0.07M | 0.06M | 0.02M | 0.01M | 0.29M |
| Change in working capital | 0.75M | 1.49M | 1.97M | 0.39M | 0.41M |
| Stock based compensation | - | 0.05M | 0.68M | - | - |
| Other non cash items | 0.66M | -4.28M | 1.51M | 9.85M | 26.36M |
| Free cash flow | -3.28M | -3.53M | -2.77M | -9.86M | -14.36M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EXL Elixinol Wellness Ltd |
- -% |
0.01 | - | 125.00 | 0.14 | 0.43 | 0.38 | -0.71 |
| AFP Aft Pharmaceuticals Ltd |
- -% |
3.59 | 29.92 | 18.18 | 1.48 | 4.37 | 2.05 | 18.56 |
| VLS Vita Life Sciences Ltd |
- -% |
2.70 | 13.50 | 42.73 | 1.52 | 2.62 | 1.19 | 7.17 |
| LGP Little Green Pharma Ltd |
- -% |
0.06 | - | 10.00 | 0.64 | 0.60 | 1.25 | 19.47 |
| MVP Medical Developments International Ltd |
- -% |
0.40 | 40.00 | 166.67 | 1.06 | 0.79 | 0.57 | 7.45 |
Elixinol Wellness Limited, a holding company, produces and sells human nutrition, human wellness, pet wellness, and superfood ingredients in Australia, the Americas, and internationally. The company offers its products under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands. It distributes its products through grocery, wholesale, and e-commerce channels for white label customers, as well as food, beverage, and beauty manufacturers. In addition, the company engages in the manufacture and distribution of hemp-derived cannabidiol (CBD) products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is based in Newtown, Australia.
51 - 53 Riversdale Road, Newtown, VIC, Australia, 3220
61 2 4044 4585
| Name | Title | Year Born |
|---|---|---|
| Mr. Ronald Dufficy BEC, FCPA | Interim Global Chief Exec. Officer | NA |
| Ms. Josephine Lorenz | Global CFO & Group Financial Controller | NA |
| Glen Zurcher | Account Director of Investor Relations Department | NA |
| Ms. Teresa Cleary | Gen. Counsel & Company Sec. | NA |
| Mr. Rob Hasselman | Pres of Americas | NA |
| Ms. Beata Silber | Global Head of R&D and Innovation | NA |
| Ms. Kim Bradley-Ware | Joint Company Sec. | NA |
| Mr. Ronald Dufficy BEC, FCPA | Group CEO, MD & Director | NA |
| Ms. Josephine Lorenz | Global CFO, Group Financial Controller & Joint Company Secretary | NA |
| Mr. Rob Hasselman | President of Americas | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.